一例具有KIAA1549-BRAF易位和致癌NF2 p.Q459*SNV的婴儿纤维肉瘤样肿瘤的新病例,具有潜在的临床意义

A. Nagy, C. Sergi, J. D. Nanassy, Lesleigh S Abbot, A. Arnoldo, C. Hawkins, B. Ngan
{"title":"一例具有KIAA1549-BRAF易位和致癌NF2 p.Q459*SNV的婴儿纤维肉瘤样肿瘤的新病例,具有潜在的临床意义","authors":"A. Nagy, C. Sergi, J. D. Nanassy, Lesleigh S Abbot, A. Arnoldo, C. Hawkins, B. Ngan","doi":"10.29328/JOURNAL.APCR.1001023","DOIUrl":null,"url":null,"abstract":"We report a case of a right gluteal mass from the sacroiliac joint to the knee of an infant girl. Biopsy showed histopathological features similar to infantile fi brosarcoma (IFS). However, unlike most IFS, no ETV6-NTRK3 fusion gene abnormality was detected. Molecular analysis with TruSight RNA Pan-Cancer Panel detected the presence of KIAA1549-BRAF translocation and an oncogenic NF2p.Q459* SNV with potential clinical signifi cance. A review revealed that the combination of this patient’s tumor site with the presence of a KIAA1549-BRAF translocation abnormality and an accompanying single nucleotide variant has not been previously described. The detection of this translocation abnormality raises the possibility that the spindle cell tumors in infants with an absence of the ETV6-NTRK3 fusion gene abnormality might have a distinct pathogenetic mechanism diff erent from the previously known IFS and congenital mesoblastic nephroma. Furthermore, the discovery of BRAF translocation and its aberrant signaling of the mitogen-activated protein kinase (MAPK) pathway in this tumor contributes to the promise of clinical benefi t of using the MEKi trametinib for the treatment of progressive disease that is refractory to conventional chemotherapy.","PeriodicalId":8289,"journal":{"name":"Archives of pathology","volume":"365 1","pages":"016-019"},"PeriodicalIF":0.0000,"publicationDate":"2021-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A novel case of an infantile fibrosarcoma-like tumor with KIAA1549 - BRAF translocation and an oncogenic NF2 p.Q459* SNV with potential clinical significance\",\"authors\":\"A. Nagy, C. Sergi, J. D. Nanassy, Lesleigh S Abbot, A. Arnoldo, C. Hawkins, B. Ngan\",\"doi\":\"10.29328/JOURNAL.APCR.1001023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We report a case of a right gluteal mass from the sacroiliac joint to the knee of an infant girl. Biopsy showed histopathological features similar to infantile fi brosarcoma (IFS). However, unlike most IFS, no ETV6-NTRK3 fusion gene abnormality was detected. Molecular analysis with TruSight RNA Pan-Cancer Panel detected the presence of KIAA1549-BRAF translocation and an oncogenic NF2p.Q459* SNV with potential clinical signifi cance. A review revealed that the combination of this patient’s tumor site with the presence of a KIAA1549-BRAF translocation abnormality and an accompanying single nucleotide variant has not been previously described. The detection of this translocation abnormality raises the possibility that the spindle cell tumors in infants with an absence of the ETV6-NTRK3 fusion gene abnormality might have a distinct pathogenetic mechanism diff erent from the previously known IFS and congenital mesoblastic nephroma. Furthermore, the discovery of BRAF translocation and its aberrant signaling of the mitogen-activated protein kinase (MAPK) pathway in this tumor contributes to the promise of clinical benefi t of using the MEKi trametinib for the treatment of progressive disease that is refractory to conventional chemotherapy.\",\"PeriodicalId\":8289,\"journal\":{\"name\":\"Archives of pathology\",\"volume\":\"365 1\",\"pages\":\"016-019\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-08-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of pathology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.29328/JOURNAL.APCR.1001023\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29328/JOURNAL.APCR.1001023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

我们报告了一例从骶髂关节到膝盖的右臀大肌肿块。活检显示组织病理学特征与婴儿纤维肉瘤(IFS)相似。然而,与大多数IFS不同,没有检测到ETV6-NTRK3融合基因异常。TruSight RNA Pan-Cancer Panel的分子分析检测到KIAA1549-BRAF易位和致癌NF2p.Q459*SNV的存在,具有潜在的临床意义。一项综述显示,该患者的肿瘤部位与存在KIAA1549-BRAF易位异常和伴随的单核苷酸变体的组合以前没有描述过。这种易位异常的检测增加了一种可能性,即缺乏ETV6-NTRK3融合基因异常的婴儿的梭形细胞肿瘤可能具有不同于先前已知的IFS和先天性中幼细胞性肾瘤的独特发病机制。此外,在该肿瘤中发现BRAF易位及其丝裂原活化蛋白激酶(MAPK)途径的异常信号传导,有助于使用MEKi-trametinib治疗传统化疗难以治疗的进行性疾病的临床益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A novel case of an infantile fibrosarcoma-like tumor with KIAA1549 - BRAF translocation and an oncogenic NF2 p.Q459* SNV with potential clinical significance
We report a case of a right gluteal mass from the sacroiliac joint to the knee of an infant girl. Biopsy showed histopathological features similar to infantile fi brosarcoma (IFS). However, unlike most IFS, no ETV6-NTRK3 fusion gene abnormality was detected. Molecular analysis with TruSight RNA Pan-Cancer Panel detected the presence of KIAA1549-BRAF translocation and an oncogenic NF2p.Q459* SNV with potential clinical signifi cance. A review revealed that the combination of this patient’s tumor site with the presence of a KIAA1549-BRAF translocation abnormality and an accompanying single nucleotide variant has not been previously described. The detection of this translocation abnormality raises the possibility that the spindle cell tumors in infants with an absence of the ETV6-NTRK3 fusion gene abnormality might have a distinct pathogenetic mechanism diff erent from the previously known IFS and congenital mesoblastic nephroma. Furthermore, the discovery of BRAF translocation and its aberrant signaling of the mitogen-activated protein kinase (MAPK) pathway in this tumor contributes to the promise of clinical benefi t of using the MEKi trametinib for the treatment of progressive disease that is refractory to conventional chemotherapy.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信